

30 The following substances, their analogs, homologs, and synthetic equivalents are listed
31 controlled substances:

32 (1) AB-001;

33 (2) AB-PINACA;

34 N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;

35 (3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)
36 methyl]-1H-indazole-3-carboxamide;

37 (4) AB-CHMINACA

38 (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

39 (5) ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
40 (cyclohexylmethyl)indazole-3-carboxamide);

41 (6) ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
42 (4-fluorobenzyl)-1H-indazole-3-carboxamide);

43 (7) AKB48;

44 (8) alpha-Pyrrolidinohexanophenone (alpha-PHP)

45 (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);

46 (9) alpha-Pyrrolidinovalerophenone (alpha-PVP);

47 (10) AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone);

48 (11) AM-1248;

49 (12) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);

50 (13) AM-2233;

51 (14) AM-679;

52 (15) A796,260;

53 (16) Butylone;

54 (17) CP 47,497 and its C6, C8, and C9 homologs (2-[(1R,3S)-3-hydroxycyclohexyl]
55 -5-(2-methyloctan-2-yl)phenol);

56 (18) Diisopropyltryptamine (DiPT);

57 (19) Ethylone;

- 58 (20) Ethylphenidate;
- 59 (21) Fluoroisocathinone;
- 60 (22) Fluoromethamphetamine;
- 61 (23) Fluoromethcathinone;
- 62 (24) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;
- 63 (25) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
- 64 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- 65 (26) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
- 66 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- 67 (27) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
- 68 (28) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
- 69 1-Pentyl-3-(1-naphthoyl)indole};
- 70 (29) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
- 71 (30) JWH-073; Naphthalen-1-yl(1-butylyndol-3-yl)methanone {also known as
- 72 1-Butyl-3-(1-naphthoyl)indole};
- 73 (31) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
- 74 (32) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
- 75 (33) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
- 76 (34) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
- 77 (35) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
- 78 (36) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
- 79 (37) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
- 80 (38) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
- 81 (39) MAM-2201;
- 82 (40) MAM-2201;
- 83 (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
- 84 (41) Methoxetamine;
- 85 (42) Naphyrone;

- 86 (43) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;
- 87 (44) Pentedrone;
- 88 (45) Pentylone;
- 89 (46) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
- 90 (47) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
- 91 BTW-8 and SR-18};
- 92 (48) STS-135;
- 93 (49) UR-144;
- 94 (50) UR-144 N-(5-chloropentyl) analog;
- 95 (51) XLR11;
- 96 (52) 2C-C;
- 97 (53) 2C-D;
- 98 (54) 2C-E;
- 99 (55) 2C-H;
- 100 (56) 2C-I;
- 101 (57) 2C-N;
- 102 (58) 2C-P;
- 103 (59) 2C-T-2;
- 104 (60) 2C-T-4;
- 105 (61) 2NE1;
- 106 (62) 25I-NBOMe;
- 107 (63) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
- 108 (64) 4-Fluoro MDMB-BUTINACA (Methyl
- 109 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate);
- 110 [~~(64)~~] (65) 4-methylmethcathinone {also known as mephedrone};
- 111 [~~(65)~~] (66) 3,4-methylenedioxypropylvalerone {also known as MDPV};
- 112 [~~(66)~~] (67) 3,4-Methylenedioxymethcathinone {also known as methylone};
- 113 [~~(67)~~] (68) 4-methoxymethcathinone;

114 [~~(68)~~] (69) 4-Methyl-alpha-pyrrolidinopropiophenone;
115 [~~(69)~~] (70) 4-Methylethcathinone;
116 [~~(70)~~] (71) 5F-AKB48;
117 1-(5-fluoropentyl)-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3- carboxamide;
118 [~~(71)~~] (72) 5-Fluoro ADB (Methyl
119 N- {[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}-3-methyl-valinate);
120 [~~(72)~~] (73) 5-Fluoro AMB (Methyl
121 N- {[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl} valinate);
122 [~~(73)~~] (74) 5-fluoro-PB-22; 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid
123 8-quinolinyl ester;
124 [~~(74)~~] (75) 5-Iodo-2-aminoindane (5-IAI);
125 [~~(75)~~] (76) 5-MeO-DALT;
126 [~~(76)~~] (77) 25B-NBOMe; 2-(*r*-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
127 methyl]ethanamine;
128 [~~(77)~~] (78) 25C-NBOMe; 2-(4Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
129 methyl]ethanamine; and
130 [~~(78)~~] (79) 25H-NBOMe;
131 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
132 Section 2. Section **58-38a-201** is amended to read:
133 **58-38a-201. Controlled Substances Advisory Committee.**
134 There is created within the Division of Occupational and Professional Licensing the
135 Controlled Substances Advisory Committee. The committee consists of:
136 (1) the director of the Department of Health or the director's designee;
137 (2) the State Medical Examiner or the examiner's designee;
138 (3) the commissioner of the Department of Public Safety or the commissioner's
139 designee;
140 (4) the director of the Bureau of Forensic Services created in Section [53-10-401](#), or the
141 director's designee;

- 142 (5) the director of the Utah Poison Control Center or the director's designee;
- 143 ~~[(4)]~~ (6) one physician who is a member of the Physicians Licensing Board and is
- 144 designated by that board;
- 145 ~~[(5)]~~ (7) one pharmacist who is a member of the Utah State Board of Pharmacy and is
- 146 designated by that board;
- 147 ~~[(6)]~~ (8) one dentist who is a member of the Dentist and Dental Hygienist Licensing
- 148 Board and is designated by that board;
- 149 ~~[(7)]~~ (9) one physician who is currently licensed and practicing in the state, to be
- 150 appointed by the governor;
- 151 ~~[(8)]~~ (10) one psychiatrist who is currently licensed and practicing in the state, to be
- 152 appointed by the governor;
- 153 ~~[(9)]~~ (11) one individual with expertise in substance abuse addiction, to be appointed
- 154 by the governor;
- 155 ~~[(10)]~~ (12) one representative from the Statewide Association of Prosecutors, to be
- 156 designated by that association;
- 157 ~~[(11)]~~ (13) one naturopathic physician who is currently licensed and practicing in the
- 158 state, to be appointed by the governor;
- 159 ~~[(12)]~~ (14) one advanced practice registered nurse who is currently licensed and
- 160 practicing in this state, to be appointed by the governor; and
- 161 ~~[(13)]~~ (15) one member of the public, to be appointed by the governor.

Section 3. Section **58-38a-202** is amended to read:

58-38a-202. Terms of committee service.

- 164 (1) (a) Members of the advisory committee shall serve terms of four years, except that
- 165 the members under Subsections **58-38a-201**(1), (2), ~~[and]~~ (3), and (4) shall serve during their
- 166 terms as appointed officials.
- 167 (b) Vacancies in the committee occurring otherwise than by the expiration of a term
- 168 shall be filled for the unexpired term in the same manner as original appointments.
- 169 (2) A member may not receive compensation or benefits for the member's service, but

170 may receive per diem and travel expenses in accordance with:

171 (a) Section 63A-3-106;

172 (b) Section 63A-3-107; and

173 (c) rules made by the Division of Finance pursuant to Sections 63A-3-106 and

174 63A-3-107.

175 (3) (a) The director of the Department of Health, or the director's designee, is the chair
176 of the committee.

177 (b) The advisory committee meets at the call of the chair or at the call of a majority of
178 the committee members.

179 (c) The advisory committee meets annually and more often as required to carry out its
180 duties under this chapter.

181 (d) Seven members of the advisory committee constitute a quorum.

182 (e) Action by the committee requires a majority vote of a quorum.